{"filings":[{"id":583958,"accession_number":"0001104659-26-065214","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2026-05-21T21:00:44+00:00","items":["7.01","9.01"],"status":"ready","headline":"VYNE and Yarrow publish investor presentation for proposed merger","summary_kind":"llm","event_type":"m_and_a","confidence":"low","bullets":["Yarrow Bioscience published an investor presentation on May 21, 2026, now available on VYNE's website.","VYNE previously filed Form S-4 (No. 333-294804) with proxy statement/prospectus for the proposed Yarrow acquisition.","Presentation provides overview of Yarrow's business as part of the pending merger with VYNE."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105566,"accession_number":"0001104659-26-026439","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2026-03-11T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"VYNE receives Nasdaq extension to Sept 7, 2026 to regain $1 bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Company failed to regain minimum $1.00 bid price by original March 10, 2026 deadline.","Nasdaq granted additional 180 calendar days, until September 7, 2026, to cure deficiency.","VYNE may consider a reverse stock split to meet the bid price requirement.","Common stock continues trading on Nasdaq Capital Market under symbol VYNE during extension."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105565,"accession_number":"0001104659-26-008642","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2026-01-30T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"VYNE amends merger with Yarrow to allow pre-funded warrants and beneficial ownership cap","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Amendment allows pre-funded warrants for Yarrow stockholders exceeding 9.99% beneficial ownership limit.","Parent Pre-Closing Dividend will also be paid to holders of VYNE warrants, per their terms.","Beneficial ownership limitation per holder set at 0%-19.99%, default 9.99%.","Amendment signed Jan 30, 2026; merger originally announced Dec 17, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121847,"accession_number":"0001104659-25-121828","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2025-12-17T23:59:59+00:00","items":["1.01","3.02","5.01","5.02","7.01","9.01"],"status":"ready","headline":"VYNE Therapeutics to merge with Yarrow Bioscience; Yarrow stockholders to own ~97% of combined company","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Pro forma ownership: pre-Merger Yarrow stockholders ~97%, VYNE stockholders ~3%.","Pre-Closing Dividend of ~$14.5M to $16.5M to VYNE stockholders prior to close.","Two concurrent financings: Yarrow Series A preferred ~$100M and Pre-Closing PIPE ~$100M.","Expected close Q2 2026; post-close board and officers designated by Yarrow."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121846,"accession_number":"0001104659-25-120637","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"VYNE Therapeutics annual meeting elects directors, ratifies auditor, approves say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Class I directors Elisabeth Sandoval Little and Steven Basta elected with ~3.9M votes each.","Baker Tilly US, LLP ratified as independent auditor for FY 2024 with 15.3M votes for.","Advisory vote on named executive officer compensation passed with 4.6M votes for.","Quorum of 50.1% of 33.3M shares outstanding at meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121845,"accession_number":"0001566044-25-000007","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"VYNE reports Q3 net loss $7.3M; cash $32.7M; strategic review ongoing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $7.3M ($0.17 per share) vs $12.2M ($0.29) in Q3 2024; revenue $0.2M from Finacea royalty.","Cash, cash equivalents and marketable securities $32.7M as of Sep 30, 2025; runway into first half 2027.","FDA partial clinical hold on VYN202 for male subjects; 12-week dog tox study ongoing to resolve.","Phase 2b repibresib gel for vitiligo failed primary endpoint F-VASI50; trial being terminated.","Board initiated strategic review in Aug 2025; evaluating partnerships, M&A, asset sales; LifeSci Capital engaged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138527,"accession_number":"0001104659-25-089531","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2025-09-12T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"VYNE receives Nasdaq bid price deficiency notice; 180-day cure period to March 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Closing bid price of VYNE common stock below $1.00 for 30 consecutive business days.","180-day compliance period until March 10, 2026; stock continues trading on Nasdaq Capital Market.","Compliance regained if bid price closes at $1.00+ for 10 consecutive trading days before deadline.","Company evaluating options; may seek second 180-day period if not compliant by March 10, 2026.","Failure to regain compliance could result in delisting of common stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138526,"accession_number":"0001104659-25-078135","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"VYNE Q2 net loss $5.8M; cash runway extended to H1 2027; two directors resign","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and marketable securities $39.6M as of Jun 30, expected to fund ops into first half of 2027.","Net loss $5.8M ($0.13 per share) vs $9.4M ($0.22) in Q2 2024; revenue $0.1M from Finacea royalty.","Directors Christine Borowski and Anthony Bruno resigned effective Aug 11 and 13, 2025; no dispute with company.","Repibresib Phase 2b vitiligo trial missed primary endpoint; company seeking partner for program.","FDA lifted clinical hold on VYN202 Phase 1b for female subjects; partial hold remains for males pending new toxicology study."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":271000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138525,"accession_number":"0001104659-25-071953","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"VYNE Phase 2b Repibresib vitiligo trial misses F-VASI50, terminates extension, seeks partner","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint F-VASI50 at Week 24 not met: 19.5% for 3% vs 23.4% vehicle (p=0.1245).","Key secondary endpoint F-VASI75 also not met (9.8% vs 6.4%, p=0.1468).","Nominal statistical significance for 3% dose on percent CFB in F-VASI (-43.6% vs -25.6%, p=0.002) and T-VASI (-28.3% vs -16.2%, p=0.044).","High vehicle effect and dropout rate in active arms (36.6% for 3% vs 10.6% vehicle); company ends trial extension phase.","Preliminary cash $39.6M as of June 30, 2025; company seeking partner for Repibresib."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155983,"accession_number":"0001628280-25-023478","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"VYNE Q1 net loss $8.6M; VYN202 psoriasis trial on clinical hold; repibresib vitiligo data due mid-2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $50.3M; net loss $8.6M ($0.20/sh) vs $6.2M in Q1 2024.","R&D expenses $6.1M, up from $3.7M, driven by VYN202 and repibresib trials.","Phase 1b psoriasis trial of VYN202 placed on clinical hold after testicular toxicity in dogs.","Repibresib gel Phase 2b vitiligo top-line results expected mid-2025; fully enrolled.","Revenue $0.2M from LEO Pharma royalty; cash runway into 2H 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":202000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174446,"accession_number":"0001628280-25-010777","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"VYNE reports FY2024 net loss $39.8M; cash $61.5M; repibresib Phase 2b data due mid-2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash & equivalents total $61.5M as of Dec 31, 2024; expected runway into 2H 2026.","Net loss for FY 2024 was $39.8M ($0.93 per share) vs $28.5M ($2.78 per share) in 2023.","R&D expenses doubled to $30.9M driven by Phase 2b repibresib and Phase 1a VYN202 trials.","Repibresib gel Phase 2b vitiligo top-line data expected mid-2025; fully enrolled ~180 subjects.","VYN202 Phase 1b psoriasis trial initiated; top-line results expected by year-end 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174445,"accession_number":"0001104659-25-002862","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"VYNE updates corporate presentation with previously announced Phase 1a data for VYN202","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Phase 1a data for VYN202 and pipeline program updates included in presentation; data was previously announced.","Presentation posted on company website and filed as Exhibit 99.1 on January 13, 2025.","No new financial results or material events disclosed in this 8-K filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191403,"accession_number":"0001104659-24-131064","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2024-12-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"VYNE reports positive Phase 1a MAD data for VYN202; no AE, robust biomarker activity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["VYN202 showed favorable safety with no drug-related AEs, including no thrombocytopenia or neutropenia.","PK supports once-daily dosing; dose-dependent exposure reached steady-state after 7 days.","Increased target engagement biomarker HEXIM-1; inhibited Th17, Th1/myeloid, Th1/Tc inflammatory biomarkers.","No drug-drug interaction when co-administered with methotrexate, a common treatment for immune conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191402,"accession_number":"0001104659-24-127997","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2024-12-12T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Stockholders approve 1.52M share increase in 2023 Equity Incentive Plan at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Increase of 1,520,000 shares to 2023 Plan; total reserve now 1,651,907 shares.","Eliminated 'liberal' share recycling for stock options and SARs.","Incentive stock option limit raised to 3,619,586 shares.","David Domzalski and Patrick LePore re-elected as Class III directors.","Baker Tilly ratified as auditor; say-on-pay approved; advisory vote set for every year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191401,"accession_number":"0001628280-24-045998","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"VYNE reports Q3 net loss $12.2M; VYN201 Phase 2b enrollment exceeds target, top-line mid-2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $12.2M ($0.29/sh) in Q3 2024 vs $6.6M ($2.01/sh) in Q3 2023, driven by higher R&D spend.","Cash and marketable securities of $70.2M; expected to fund operations through end of 2025.","VYN201 Phase 2b vitiligo trial enrollment exceeded target; fully enrolled Dec 2024, top-line mid-2025.","VYN202 Phase 1a SAD data positive; MAD data expected Q4 2024. Plans for Phase 1b in psoriasis and RA.","R&D expenses rose 208.9% to $10.2M due to advancing clinical trials."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":417000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207887,"accession_number":"0001104659-24-099121","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2024-09-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"VYNE Therapeutics reports positive Phase 1a SAD data for VYN202; no drug-related adverse events","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["VYN202 well tolerated across all dose groups; no serious or drug-related AEs, no clinically significant lab/ECG abnormalities.","PK results showed dose-dependent exposure of VYN202 in plasma and urine across all doses tested.","PD activity observed: increased HEXIM1 (target engagement) and inhibitory effect on inflammatory biomarkers for psoriasis and rheumatoid arthritis.","Dosing in the multiple ascending dose (MAD) portion of Phase 1a has begun; results expected Q4 2024.","CEO David Domzalski highlighted milestone for the company's BD2-selective BET inhibitor platform."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207886,"accession_number":"0001628280-24-037051","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"VYNE Therapeutics Q2 2024 net loss $9.4M; cash $78.1M funds milestones into 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $9.4M ($0.22 EPS) vs $10.1M ($3.09 EPS) in Q2 2023.","Cash, cash equivalents, restricted cash and marketable securities of $78.1M as of June 30, 2024.","Initiated Phase 2b trial of VYN201 in nonsegmental vitiligo; top-line results expected mid-2025.","Phase 1a SAD/MAD trial of VYN202 ongoing; SAD data in Q3 2024, MAD data in Q4 2024.","Appointed Dr. Subhashis Banerjee as SVP of Clinical Development; previously at Bristol Myers Squibb."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":296000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225357,"accession_number":"0001628280-24-021971","cik":1566044,"company_name":"VYNE Therapeutics Inc.","ticker":"VYNE","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"VYNE reports Q1 2024 net loss of $6.2M, cash $86M; vitiligo Phase 2b trial on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents, restricted cash and marketable securities of $86.0M as of March 31; runway through end of 2025.","Net loss $6.2M ($0.15/sh) vs $5.6M ($1.74/sh) in Q1 2023; R&D expense up 35.6% to $3.7M.","Phase 2b trial for VYN201 in nonsegmental vitiligo to enroll ~160 subjects in 1%,2%,3% gel vs vehicle; first dose expected Q2 2024.","IND cleared for oral BET inhibitor VYN202; Phase 1a SAD/MAD starting Q2 2024 with top-line data H2 2024.","Top-line Phase 2b data expected mid-2025; Phase 1b trials in psoriasis and RA planned for H2 2025 if Phase 1a successful."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":98000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":22720000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}